Compare Gigacloud Technology Inc (GCT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gigacloud Technology Inc trades at $51 (market cap $1.84B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 73× Gigacloud Technology Inc's market cap. Which is the better fit depends on your goals.
| GCT | VRTX | |
|---|---|---|
Market Cap | $1.84B | $134.25B |
Sector | Technology | Health |
52-Week High | $53.25 | $529.65 |
52-Week Low | $25.44 | $376.62 |
Enterprise Value | $1.97B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $53.25, up 1.62% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.16 versus $0.90 expected, and maintains a 10.65% net income margin. Revenue growth is projected from $1.29B in 2025 to $1.5B in 2026, supported by positive cash flow generation of $120.10M in 2025.
The outlook remains positive given strong profitability metrics (32.34% ROE) and analyst consensus favoring Buy ratings (66.67%). Key risks include potential margin pressure from higher costs and competitive threats in the B2B logistics space. The stock's current valuation at 12.3x P/E appears reasonable relative to growth prospects, though technical indicators show overbought conditions with RSI above 85.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
